Loading…
Loading…
See exactly how IHE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IHE and 80,000+ other tickers.
The iShares U.S. Pharmaceuticals ETF is designed to replicate the investment performance of a benchmark index. This index consists solely of equity securities from pharmaceutical companies operating within the United States.
Vanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the last five years but carries higher concentration risk with only 56 holdings Vanguard Health Care ETF provides broader sector diversification by covering the entire medical ecosystem while the iShares fund focuses strictly on drug manufacturers
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a barrel. MSCI's Asia-Pacific gauge outside Japan gained 1.2%, while South Korea's Kospi surged more than 6% and Japan's Nikkei 225 climbed 1.9%.
IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.
iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF
The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.